First quarter 2025 GAAP net income of $3.1 million or $0.27 per basic weighted average common share and Distributable Earnings(1) of $3.5 million or $0.31 per basic weighted average common shareWEST PALM BEACH, Fla., May 07, 2025 (GLOBE NEWSWIRE) -- Sunrise Realty Trust, Inc. (NASDAQ:SUNS) (“SUNS” or the “Company”) today announced its results for the quarter ended March 31, 2025. SUNS reported generally accepted accounting principles (“GAAP”) net income of $3.1 million or $0.27 per basic weighted average co ...

Announces successful completion of sub-chronic and chronic toxicology studies for INF904, supporting long-term dosing in future clinical trialsMultiple near-term catalysts anticipated with the potential to substantially de-risk the Company's pipeline addressing multiple sizable marketsInterim analysis for vilobelimab Phase 3 trial in pyoderma gangrenosum (PG), to determine trial size adaptation or futility, remains on schedule with a recommendation expected to be announced at the end of May to early JuneTop ...

Valour Launches CRV and LTC ETPs on Spotlight: Valour, a subsidiary of DeFi Technologies, has listed the Valour Curve DAO (CRV) and Valour Litecoin (LTC) SEK ETPs on Sweden’s Spotlight Stock Market, further expanding its Nordic footprint.Comprehensive Digital Asset Exposure: With over 65 ETPs live, Valour is advancing toward its 100 ETP goal with new single-asset, thematic basket, and leveraged products—including upcoming listings for Tron (TRX), Stellar (XLM), BTC 2x, and ETH 2x.Continued Product Innovatio ...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVANCOUVER, BC, May 07, 2025 (GLOBE NEWSWIRE) -- Eat & Beyond Global Holdings Inc. (CSE: EATS) (OTCPK: EATBF) (FSE: 988) (“Eat & Beyond” or the “Company”), an investment issuer focused on incubating first-mover opportunities in emerging markets, is pleased to announce, further to its news release of January 31, 2025, that the Company has completed the acquisition of 100% of the issued and outstanding common shares in the ...

Q1-2025 Net Income of $3.3 million Robust EBITDA1 of $15.2 million and Free Cash Flow to Equity1 of $4.8 million 15th Quarterly Dividend of Cdn$.03 Declared $4.6 million Returned through Dividends and Share Buybacks in Q1-2025 VANCOUVER, British Columbia, May 07, 2025 (GLOBE NEWSWIRE) -- Amerigo Resources Ltd. (TSX: ARG; OTCQX: ARREF) (“Amerigo” or the “Company”) is pleased to announce a strong financial performance for the three months ended March 31, 2025 (“Q1-2025”). Dollar amounts in this news release a ...

Key Highlights Refreshed brand identity reflects Matador’s evolution into a vertically integrated Bitcoin-focused company.Core strategy: hold Bitcoin, launch Bitcoin-native products, and reinvest proceeds into additional BTC.Introduction of the Matador Bitcoin Model: a self-reinforcing approach combining treasury management, infrastructure development, and ecosystem engagement.Proposed change of business to a Technology/Investment Issuer provides greater operational and strategic flexibility.Matador is a pa ...

WALTHAM, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the following May investor conferences. RBC Capital Markets’ 2025 Global Healthcare Conference, being held in New York on May 20-21. Jason K. Garland, Chief Financial Officer, is scheduled to participate in an analyst-led discussion on May 20 at 3:35 p.m. ET, in addition to a series of one-on-one meetings ...

PALO ALTO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will participate in a fireside chat at the Bank of America Merrill Lynch Global Healthcare Conference 2025 in Las Vegas, NV on Wednesday, May 14 at 2:20 pm PT. To access the live webcast of BridgeBio’s presentation, please visit the “Events” page within the Investors s ...

- End-of-Phase 2 meeting with FDA requested for Alzheimer’s disease - - Phase 2 results in dementia with Lewy bodies accepted for oral presentation at AAIC - - Two posters at ARVO describe zervimesine's role supporting retinal cell health - PURCHASE, N.Y., May 07, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, today reported financial results for the first quarter ended Ma ...

TORONTO, May 07, 2025 (GLOBE NEWSWIRE) -- Abaxx Technologies Inc. (CBOE:ABXX)(OTCQX:ABXXF) (“Abaxx” or the “Company”), a financial software and market infrastructure company, majority shareholder of Abaxx Singapore Pte Ltd., the owner of Abaxx Commodity Exchange and Clearinghouse (individually, “Abaxx Exchange” and “Abaxx Clearing”), and producer of the SmarterMarkets™ Podcast, today announced the successful first delivery under a carbon futures contract on Abaxx Exchange. The delivery, involving 50 lots of ...